DBD. Allan Butterfield

D. Allan Butterfield

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


D. Allan Butterfield has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Sridhar Varadarajan

    Department of Chemistry and Center of Membrane Sciences, University of Kentucky, Lexington, Kentucky

    4 shared publications
  • Jaroslaw Kanski

    3 shared publications
  • Servet M. Yatin

    Department of Chemistry and Center of Membrane Sciences, University of Kentucky, Lexington, 40506-0055, USA

    3 shared publications
  • Beverly J. Howard

    2 shared publications
  • Jennifer Drake

    Department of Chemistry and Center of Membrane Sciences, University of Kentucky, Lexington, Kentucky, 40506, USA

    2 shared publications
  • Servet Yatin

    Department of Chemistry and Center of Membrane Sciences, University of Kentucky, Lexington, Kentucky 40506‐0055, USA

    2 shared publications

Latest Publications

  • Oxidative stress in Alzheimer disease and mild cognitive impairment: evidence from human data provided by redox proteomics

    by Aaron M. Swomley, D. Allan Butterfield

    Alzheimer disease (AD) is a neurodegenerative disease with many known pathological features, yet there is still much debate into the exact cause and mechanisms for progression of this degenerative disorder. The amyloid-beta (Aβ)-induced oxidative stress hypothesis postulates that it is the oligomeric Aβ that inserts into membrane systems to initiate much of the oxidative stress observed in brain during the progression of the disease. In order to study the effects of oxidative stress on tissue from patients with AD and amnestic mild cognitive impairment (MCI), we have developed a method called redox proteomics that identifies specific brain proteins found to be selectively oxidized. Here, we discuss experimental findings of oxidatively modified proteins involved in three key cellular processes implicated in the pathogenesis of AD progression: energy metabolism, cell signaling and neurotransmission, as well as the proteasomal degradation pathways and antioxidant response systems. These proteomics studies conducted by our laboratory and others in the field shed light on the molecular changes imposed on the cells of AD and MCI brain, through the deregulated increase in oxidative/nitrosative stress inflicted by Aβ and mitochondrial dysfunction.


  • Elevation of brain glutathione by γ‐glutamylcysteine ethyl ester protects against peroxynitrite‐induced oxidative stress

    by Jennifer Drake, Jaroslaw Kanski, Sridhar Varadarajan, Maria Tsoras, D. Allan Butterfield

    Elevation of glutathione (GSH) has been recognized as an important method for modulating levels of reactive oxygen species (ROS) in the brain. We investigated the antioxidant properties of γ‐glu‐cys‐ethyl ester (GCEE) in vitro and its ability to increase GSH levels upon in vivo i.p. injection. GCEE displays antioxidant activity similar to GSH as assessed by various in vitro indices such as hydroxyl radical scavenging, dichlorofluorescein fluorescence (DCF), protein specific spin labeling, glutamine synthetase (GS) activity, and protein carbonyls. Intraperitoneal injection of GCEE to gerbils resulted in a 41% increase in brain total GSH levels in vivo as determined by the DTNB‐GSH reductase recycling method. Gerbils injected with buthionine sulfoximine (BSO), an inhibitor of γ‐glutamylcysteine synthetase, had 40% less total brain glutathione. Gerbils injected with BSO followed by a GCEE injection had GSH levels similar to vehicle‐injected controls, suggesting that GCEE upregulates GSH biosynthesis by providing γ‐glutamylcysteine and not cysteine. Cortical synaptosomes from GCEE‐injected animals were less susceptible to peroxynitrite‐induced oxidative damage as assessed by DCF fluorescence, protein‐specific spin labeling, and GS activity. These experiments suggest that GCEE is effective in increasing brain GSH levels and may potentially play an important therapeutic role in attenuating oxidative stress in neurodegenerative diseases associated with oxidative stress such as Alzheimer disease.


  • Top Cited Papers

    Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide

    by D.Allan Butterfield, Jennifer Drake, Chava Pocernich, Alessandra Castegna


  • The glial glutamate transporter, GLT‐1, is oxidatively modified by 4‐hydroxy‐2‐nonenal in the Alzheimer's disease brain: the role of Aβ1–42

    by Christopher M. Lauderback, Janna M. Hackett, Feng F. Huang, Jeffrey N. Keller, Luke I. Szweda, William R. Markesbery, D. Allan Butterfield

    Glutamate transporters are involved in the maintenance of synaptic glutamate concentrations. Because of its potential neurotoxicity, clearance of glutamate from the synaptic cleft may be critical for neuronal survival. Inhibition of glutamate uptake from the synapse has been implicated in several neurodegenerative disorders. In particular, glutamate uptake is inhibited in Alzheimer's disease (AD); however, the mechanism of decreased transporter activity is unknown. Oxidative damage in brain is implicated in models of neurodegeneration, as well as in AD. Glutamate transporters are inhibited by oxidative damage from reactive oxygen species and lipid peroxidation products such as 4‐hydroxy‐2‐nonenal (HNE). Therefore, we have investigated a possible connection between the oxidative damage and the decreased glutamate uptake known to occur in AD brain. Western blots of immunoprecipitated HNE‐immunoreactive proteins from the inferior parietal lobule of AD and control brains suggest that HNE is conjugated to GLT‐1 to a greater extent in the AD brain. A similar analysis of beta amyloid (Aβ)‐treated synaptosomes shows for the first time that Aβ1–42 also increases HNE conjugation to the glutamate transporter. Together, our data provide a possible link between the oxidative damage and neurodegeneration in AD, and supports the role of excitotoxicity in the pathogenesis of this disorder. Furthermore, our data suggests that Aβ may be a possible causative agent in this cascade.


  • Brain Oxidative Stress in Animal Models of Accelerated Aging and the Age-related Neurodegenerative Disorders, Alzheimers Disease and Huntingtons Disease

    by D. Allan Butterfield, Beverly J. Howard, Michael A. LaFontaine

    Oxidative stress in brain is emerging as a potential causal factor in aging and age-related neurodegenerative disorders. Brain tissue from living patients is difficult to acquire; hence, animal models of aging and age-related neurodegenerative disorders, though not perfect models, have provided tissue to study the role of oxidative stress in these disorders. In this review, the central role of oxidative damage in brain in models of accelerated aging (progeria and Werners syndrome) and the age-related neurodegenerative disorders, Alzheimers disease and Huntingtons disease, will be presented and evaluated. To the extent that the animal models faithfully mirror their respective disorders, and based on the totality of the studies, it is apparent that oxidative stress, the excess of free radicals over the means of scavenging these harmful agents, may play critical roles in the molecular basis of accelerated aging, Alzheimers disease, and Huntingtons disease.


  • Role of spermine in amyloid ?-peptide-associated free radical-induced neurotoxicity

    by Servet M. Yatin, Mustafa Yatin, Sridhar Varadarajan, Kenneth B. Ain, D. Allan Butterfield

    The polyamines, relatively low-molecular-weight aliphatic compounds, are the main inducers of eukaryotic cell growth and proliferation. Although polyamine requirements for cell growth are well defined, their role is still enigmatic. We have previously reported that amyloid β-peptide (Aβ), the main constituent of senile plaques in Alzheimer's disease (AD) brain, is toxic to neurons through a free radical-dependent oxidative stress mechanism and that Aβ(1–42), the principal form of Aβ in AD brain, causes an increase in polyamine metabolism manifested by up-regulated polyamine uptake and increased ornithine decarboxylase (ODC) activity. Both effects were prevented by the free radical scavenger vitamin E. Spermine has been reported to function directly as a free radical scavenger. In the current study, we aimed to address whether up-regulation of polyamine metabolism is a defense against, or a result of, Aβ-induced oxidative stress by investigating the capability of spermine to quench Aβ-associated free radicals in solution and to assert a protective function of spermine in neuronal culture against Aβ. Pretreatment of cultured neurons with spermine prior to Aβ exposure failed to prevent Aβ-induced cell death. Indeed, Aβ plus spermine added to cultured neurons was even more neurotoxic than either agent alone. Additionally, inhibition of the polyamine synthesis by difluoromethylornithine (DFMO) did not protect cells from Aβ-induced free radical toxicity, and stimulation of the synthesis of putrescine and spermine by the aminopropyltransferase inhibitor S-adenosyl-1,8-diamino-thiooctane (AdoDATO), rather, further enhanced Aβ-induced toxicity. Although spermine is capable of scavenging free radicals generated by Aβ in solution as measured by electron paramagnetic resonance (EPR) spectroscopy, the up-regulated transport of exogenously added spermine together with Aβ may lead to overaccumulation of a cellular spermine pool, with resulting enhanced neurotoxicity. J. Neurosci. Res. 63:395–401, 2001.


  • Open Access

    Effect of Exogenous and Endogenous Antioxidants on 3‐Nitropionic Acid‐Inducedin vivo Oxidative Stress and Striatal Lesions

    by Michael A. La Fontaine, James W. Geddes, Andrea Banks, D. Allan Butterfield

    3‐Nitropropionic acid (3‐NP) is an irreversible inhibitor of complex II in the mitochondria. 3‐NP toxicity has gained acceptance as an animal model of Huntington's disease (HD). In the present study, we confirmed that rats injected with 3‐NP (20 mg/kg, i.p., daily for 4 days) exhibit increased oxidative stress in both striatum and cortical synaptosomes as well as lesions in the striatum. Synaptosomal membrane proteins from rats injected with 3‐NP exhibited a decrease in W/S ratio, the relevant electron paramagnetic resonance (EPR) parameter used to determine levels of protein oxidation, and western blot analysis for protein carbonyls revealed direct evidence of increased synaptosomal protein oxidation. Treatment of rats with the brain‐accessible free radical spin trap 5‐diethoxyphosphoryl‐5‐methyl‐1‐pyrroline N‐oxide (DEPMPO; 30 mg/kg, i.p., daily 2 h before 3‐NP injection) or with N‐acetylcysteine (NAC; 100 mg/kg, i.p., daily 2 h before 3‐NP injection), a known glutathione precursor, before 3‐NP treatments protects against oxidative damage induced by 3‐NP as measured by EPR and western blot analysis for protein carbonyls. Furthermore, both DEMPMPO and NAC treatments before 3‐NP administration significantly reduce striatal lesion volumes. These data suggest oxidative damage is a prerequisite for striatal lesion formation and that antioxidant treatment may be a useful therapeutic strategy against 3‐NP neurotoxicity and perhaps against HD as well.


  • Formation of a protein-bound pyrazinium free radical cation during glycation of histone H1

    by Georg T Wondrak, Sridhar Varadarajan, D.Allan Butterfield, Myron K Jacobson